Lilly Ready To Take Oral RA Drug Baricitinib To Finish Line
This article was originally published in The Pink Sheet Daily
Executive Summary
If all goes well, the plan is to file once-daily JAK inhibitor in rheumatoid arthritis by the end of the year and to launch in the first quarter of 2017, says Lilly’s global medical launch leader Birgit Kovacs.